VENUS NGUYEN: Open Payments
NPI 1053705087 · EL CENTRO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$416 in 11 payments from 7 companies in 2025. Trend: 2023 $154 · 2024 $177 · 2025 $416
Food & beverage: $416
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 4 | $164 |
| Novo Nordisk Inc | 1 | $89 |
| GlaxoSmithKline, LLC. | 2 | $65 |
| Madrigal Pharmaceuticals | 1 | $37 |
| Hologic Sales and Service, LLC | 1 | $24 |
| ABIOMED | 1 | $22 |
| Astellas Pharma US Inc | 1 | $17 |
Products named: TEZSPIRE, Wegovy, AREXVY, FARXIGA, REZDIFFRA, APTIMA, AIRSUPRA, Veozah.
Industry payments across CA — which companies pay providers there.
